PCRC_A211201

Change in Mammographic Density With Metformin Use: A Companion Study to NCIC Study MA.32

This trial studies changes in breast density in patients with early-stage breast cancer treated with metformin hydrochloride or placebo on CAN-NCIC-MA.32.

Key Eligibility:

* Patients must either be concurrently enrolling or previously enrolled to Canada (CAN) National Cancer Institute of Canada (NCIC) study MA.32 (CAN-NCIC-MA.32) (MA.32); eligible patients may be either pre- or post-menopausal.

* Patients must have hormone receptor-negative breast cancer.

* Patients must have breast density ≥ 25% (correlating with the Breast Imaging-Reporting and Data [BIRAD]-2 category of scattered fibroglandular densities or greater).
N/A
NCT01666171
Oncology
Breast
Alison Conlin, M.D.
Alliance
Nikki Moxon

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.